77 results about "Thyroid carcinoma" patented technology

The invention discloses a Faster RCNN-based papillary thyroid carcinoma ultrasonic image recognition method and system. The method comprises the steps that a training sample including an ultrasonic image and the corresponding diagnosis result is acquired, wherein the ultrasonic image is the image obtained by performing ultrasonic imaging on the papillary thyroid carcinoma affected region of the patient; a Faster RCNN network to be trained based on a ZF network is trained by using the training sample so as to obtain a corresponding trained model, wherein the Faster RCNN network to be trained is the Faster RCNN network obtained after connection of the fourth layer and the fifth layer in the shared convolutional layer; and when the ultrasonic image to be detected is acquired, the ultrasonic image to be detected is inputted to the trained model so as to obtain the detection result outputted by the trained model. The used Faster RCNN network is obtained after connection of the fourth layer and the fifth layer in the shared convolutional layer so that the effect that the output characteristics of the fourth layer and the fifth layer can be converged into a path of characteristic flow can be achieved, and the accuracy of image recognition can be effectively enhanced.

The present invention relates to methods, compositions and articles directed to diagnosing thyroid carcinoma, differentiating between thyroid carcinoma and benign thyroid diseases, testing indeterminate thyroid fine needle aspirate samples of thyroid nodules, and determining patient protocols and outcomes.

The invention discloses a papillary thyroid carcinoma lymph node metastasis prediction method based on Transform-MIL. The method comprises the following steps: S1, extracting the characteristics of patch in WSI by using a lightweight ViT network; s2, selecting a key path by adopting a clustering-based strategy; s3, constructing a Transform-MIL model, learning relationships among instances from multiple aspects through a multi-head self-attention mechanism, and embedding instance-level features into packet representation; s4, combining a thyroid papillary set and a lymph node metastasis data set, and helping a Transform-MIL model to learn and predict lymph node metastasis through mutual knowledge distillation; according to the method, the Transform-MIL model is constructed, the instance-level features are better embedded into the packet representation, the morphological similarity between the tumor cells and the lymph node metastasis cells is fully utilized, and the knowledge of the relationship between the two data sets is transmitted by taking the attention map as a medium, so that the prediction accuracy of the lymph node metastasis histopathology image is improved.

A Chinese medicine for treating cancers and tumors is prepared from 17 Chinese-medicinal materials including ginseng, Chinese angelica root, Chuan-xiong rhizome, peach kernel, safflower, etc. Its advantages are sure curative effect and no toxic by-effect.

The invention relates to a Chinese medicinal pill for treating cancer, which is prepared from house lizard, ganoderma lucidum, paris rhizome, cow-bezoar, root of American ginseng and raw licorice root.

The present invention pertains to the use of subunits and oligomers of mannan-binding lectin (MBL) in prophylactic and/or curative treatment of an immunocompromised individual such as subjects suffering from solid tumors or haematological cancers. Solid tumors include such as female cancers, male cancers, cancers of the respiratory system, cancers of the gastro intestinal system, the renal system and further subjects suffering from thyroid cancer and melanomas. Haematological cancers include leukaemia, lymphoma and myeloma. The immunocompromised condition of the individual may be due to a cancer disease as mentioned herein or the treatment of said cancer disease.

Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

The invention discloses a monoclonal antibody for mouse anti-human type BRAF V600E mutant protein. The monoclonal antibody is high in specificity, stable in expression and high in potency, can be applied to BRAF V600E mutant protein in malignant tumors, and has a certain medicine-based research value. The invention also relates to application of the monoclonal antibody to preparation of an immunohistochemical detecting tool for detecting the BRAF V600E mutant protein. According to the monoclonal antibody and the application of the monoclonal antibody disclosed by the invention, an immunohistochemical technology based on the BRAF V600E monoclonal antibody is built and is used in auxiliary diagnosis, selection of treatment schemes and prognosis of the malignant tumors, wherein the malignanttumors mainly comprise malignant melanoma, lung adenocarcinoma, colorectal carcinoma, gastrointestinal stromal tumors, papillary thyroid carcinoma, astrocytoma, hairy cell leukemia, lynch syndrome andthe like. Based on simple operation and less charging of the immunohistochemical method, the method can be used as a first-choice detection method of BRAF V600E gene mutation in clinic work.

The invention discloses a specific primer combination for identifying RET gene mutation of medullary thyroid carcinoma. The specific primer combination is characterized in that the combination is usedfor amplifying a sequence shown in SEQ ID NO.1 in RET gene mutation of medullary thyroid carcinoma. The primer combination comprises a combination of a primer RET8, a primer RET10, a primer RET11, aprimer RET13, a primer RET14, a primer RET15 and a primer RET16. The invention further discloses a kit of the primer combination and an application of the primer combination. The primer combination ishigh in specificity, covers targeted area fragments accurately and detects various known mutant sites. By adopting a mixed solution of the specific primers and marks with fluorescent edges to carry out PCR amplification on batched samples and sanger sequencing analysis, a lot of samples can be analyzed at one time, and various known and unknown mutation can be detected, so that the operating steps are reduced, the resources are saved and the efficiency is improved. A kit provided by the invention can be widely applied to assisted diagnostic detection of clinical medullary thyroid carcinoma and has a wide application prospect.

The invention provides a papillary thyroid carcinoma distant metastasis mutation predicting model, a predicting model method and a predicting model system. The papillary thyroid carcinoma distant metastasis mutation predicting model realizes high predicting accuracy which is higher than that of a currently reported model. Furthermore the papillary thyroid carcinoma distant metastasis mutation predicting model has high sensitivity and high specificity. Furthermore researching of the invention proves a fact that TERT starter mutation has no evident correlation with distant metastasis, and furthermore chr22q loss and gene fusion are remarkably correlated with distant metastasis. The samples of the invention are obtained from Chinese people, and foreign researching samples are obtained from the Western country people. Therefore the researching result of the invention has higher application value for the Chinese people.

The invention relates to an intelligent drug controlled release system which is formed by adding organic phosphate component into polyelectrolyte capsule wall. The intelligent drug controlled release system has the advantages that the component of the polyelectrolyte capsule can respond to the concentration of acid phosphatase in the blood serum of a patient with tumour and influence the permeability of the capsule wall to achieve the effect of releasing drugs intelligently; and as a tumour marker, the acid phosphatase is used for observing the development and treatment effect of the tumour in the clinical work. The vitality increase of removed blood serum of the patient with prostate cancer can be dozens of times normal value, and the acid phosphatase in the blood serum of the patients with stomach cancer, colon cancer, breast cancer, hypothyroid cancer, kidney cancer, ovary cancer, malignant lymphogranulomatosis and multiple myeloma can also have moderate increase, therefore, a drug loaded polyelectrolyte capsule intelligent drug controlled release system with the acid phosphatase as the response can process drug controlled release treatment on various tumors. The intelligent drug controlled release system uses the tumour marker phosphatase as the drug controlled release condition, so the intelligent drug controlled release system has better practical application meaning.

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

It is an object of the present invention to identify a gene that exhibits behavior which is characteristic of carcinomas such as thyroid carcinoma, so as to provide a method for detecting carcinoma and a cell growth suppressing agent. The present invention provides a method for detecting carcinoma, which comprises detecting malignant transformation by detecting at least one alteration of gene existing in chromosomal regions 1q41, 3q28, 7q31.2, 8p12, 8q22.2, 8q24.21, 11q4.1, 17q12, 20q11, 9p21.3, 16q13.2, and 16q23.1 in a specimen.

Compounds represented by Formula (I):

or a pharmaceutically acceptable salt or N-oxide thereof, wherein A and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.

The invention relates to a serum tRF marker used for PTC diagnosis. Secondly, the invention provides application of a reagent used for detecting an expression quantity of the tRF in the serum in preparation of a PTC diagnosis preparation. Finally, the invention provides a PTC diagnosis kit, the PTC diagnosis kit can measure the content of the tRF in the serum, and the nucleotide sequence of the serum marker is disclosed by SEQ ID NO.1. When a tRF molecule provided by the invention and a specific primer of the tRF molecule are taken as the diagnosis reagent, the diagnosis accuracy of the PTC can be further improved, help is provided for clinical doctors to quickly master the state of an illness of a patient and formulate a diagnosis and treatment scheme, and a foundation is laid for discovering a novel small molecule targeted medicine with a potential treatment value.

The invention belongs to the field of medicines and particularly relates to a pharmaceutical preparation for metastatic bone pain of thyroid cancer and a preparation method of the pharmaceutical preparation. The pharmaceutical preparation is prepared from Cantonese Speranskia, Herba Leontopodii Subulati, Herba Speranskiae Tuberculatae, Cortex Eucommiae, Radix Rehmanniae Preparata, Herba Taxilli, Herba Siegesbeckiae, Dindygulen Peperomia Herb, Eupolyphaga seu Steleophaga, Rhizoma Panacis Japonici, Herba Cyperi Micheliani and Radix Polyalthiae Nemoralis. The pharmaceutical preparation has efficacies of blood circulation promoting, stasis removing, pain relieving, heat clearing, detoxifying, kidney tonifying and bone strengthening and is capable of effectively regulating functional balance of body Yin and Yang, Qi, blood and internal organs, relieving pains, resisting cancers, well improving immune functions of patients, improving disease resistance, reducing toxic and side effects of radiotherapy and chemotherapy and evidently improving life quality of the patients.

The present invention provides a set of moieties specific for tumor markers, in particular of follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC) as well as a method for identifying markers of any genetic disease.

The invention discloses a traditional Chinese medicine composition. The preparation method of the traditional Chinese medicine composition consists of: putting Paphiopedilum concolor, Resina Liquidamberis, coix seed, pangolin, kelp, Desmodium racemosum Thunb, Knoxia Root, Curculigo orchioides, japanese spicebush bark, Leonurus pseudo-macranthus, turtle shell, anemarrhena, Caulis Trachelospermi, rhizoma arisaematis, polygala tenuifolia, lycoris radiate, Amaranthus tricolor seed, semen plantaginis, rhodiola rosea, prunella vulgaris, cavalerie mosla herb, Gynura bicolor, Ilex chinensis, chicken's gizzard-membrane, Feather Cockscomb Seed, Iphigenia indica, Rorippa globosa, natural indigo, reed rhizome, Ranunculus ternatus, Hoya carnosa, tortoise shell, Zaocys dhumnades, Peliosanthes minor Yamamoto rhizome, Calystegia soldanella, fructus psoraleae, rhizoma bolbostemmatis, rhizoma corydalis, Cirsium japonicum, Rhodomyrtus tomentosa Hassk, Chinese Floweringquince Fruit, Caulis Clematidis Armandii, polyporus, Curcuma zedoaria, licorice, fleshfingered citron distillate, radix bupleuri, Chinese honeylocust spine, Senecio scandens, Adenophora trachelioides Maxim and buffalo horn in an earthen pot, adding water and performing decoction over big fire, then conducting decoction over soft fire, performing filtering, and taking the first decocted fluid; adding water into the filtered drug residue, performing decoction over big fire, then conducting decoction over soft fire, performing filtering, and taking the second decocted fluid; combining the two decocted fluid, boiling the combined decocted fluid over strong fire, and conducting decoction concentration on soft fire to a remaining medicinal liquid of 300-400mL, thus obtaining the medicinal liquid for oral taking.